Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 501–600 of 1,000
Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma
Sun, W.-Y., Jung, W.-H., & Koo, J. S. (2015) · Tumor Biology · doi:10.1007/s13277-015-4684-4 · Cited by 50
Qiu, X., Zhang, F.-F., Geng, F., Liu, C., Xu, P., Lu, Z.-Z., Yu, B., Wu, H., Wu, J., Zhang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1827-4 · Cited by 50
Revisiting ovarian cancer microenvironment: a friend or a foe?
Zhang, B., Chen, F., Xu, Q., Han, L., Xu, J., Gao, L., Sun, X., Li, Y., Li, Y., Qian, M., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0466-7 · Cited by 51
“This change is accompanied by increased TNF-α+ and CD80+ macrophage infiltration, together with elevated TNF-α and the monocyte chemotactic protein 1 (MCP-1, or CCL2) in bronchoalveolar lavage fluid of the lung, suggesting anticancer IgE reprograms macrophages in the TME (Josephs et al., 2017).”
BackgroundInfluentialModern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
Lan, C., Kitano, Y., Yamashita, Y., Yamao, T., Kajiyama, K., Yoshizumi, T., Fukuzawa, K., Sugimachi, K., Ikeda, Y., Takamori, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01569-6 · Cited by 51
Dziadek, S., Kraxner, A., Cheng, W., Yang, T.-H. O., Flores, M., Theiss, N., Tsao, T., Andersson, E. K., Harring, S. V., Bröske, A.-M. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352615 · Cited by 49
Understanding the complexity and malleability of T‐cell recognition
Miles, J. J., McCluskey, J., Rossjohn, J., & Gras, S. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.112 · Cited by 54
Targeting immunosuppression for cancer therapy
Ghirelli, C., & Hagemann, T. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69999 · Cited by 49
Molecular Pathways: Myeloid Complicity in Cancer
Stromnes, I. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0866 · Cited by 51
Pancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & Pasca di Magliano, M. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
O’Connor, R. A., Chauhan, V., Mathieson, L., Titmarsh, H. F., Koppensteiner, L., Young, I., Tagliavini, G., Dorward, D. A., Prost, S., Dhaliwal, K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1940675 · Cited by 52
Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer
Jung, Y. Y., Lee, Y. K., & Koo, J. S. (2015) · Tumor Biology · doi:10.1007/s13277-015-3594-9 · Cited by 50
Wu, M., Wang, Y., Yang, Q., Wang, X., Yang, X., Xing, H., Sang, X., Li, X., Zhao, H., & Huo, L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265712 · Cited by 49
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Corvigno, S., Wisman, G. B. A., Mezheyeuski, A., van der Zee, A. G. J., Nijman, H. W., Åvall-Lundqvist, E., Östman, A., & Dahlstrand, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7613 · Cited by 46
“Differential expression of markers such as alpha smooth muscle actin (α-SMA), platelet derived growth factor beta receptor (PDGFβR), podoplanin and fibroblast activation protein (FAP) [18, 19] may account for different features and functions.”
Jia, J., Martin, T. A., Ye, L., Meng, L., Xia, N. L., Jiang, W. G., & Zhang, X. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3224 · Cited by 48
Zou, M., Zheng, B., Liu, F., Wang, X., Hu, J.-R., Huang, W., Dai, Z., Zhang, Q.-S., Liu, F.-B., Zhong, H., et al. (2019) · Neurosurgery · doi:10.1093/neuros/nyz333 · Cited by 53
Gong, L., Kwong, D. L., Dai, W., Wu, P., Wang, Y., Lee, A. W. M., & Guan, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.744889 · Cited by 52
“Targeting fibroblasts with high expression of fibroblast activation protein-a (FAP) in tumor-bearing mice have induced tumor necrosis mediated by IFN-g and TNF-a, demonstrating that anti-tumor immunity has been reverted upon depletion of these cells (125).”
BackgroundFibroblast Activation Protein Expression in Sarcomas
Crane, J. N., Graham, D. S., Mona, C. E., Nelson, S. D., Samiei, A., Dawson, D. W., Dry, S., Masri, M. G., Crompton, J. G., Benz, M., et al. (2023) · Sarcoma · doi:10.1155/2023/2480493 · Cited by 48
Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 49
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Cancer-Associated Fibroblasts in Pancreatic Adenocarcinoma
Pan, B., Liao, Q., Niu, Z., Zhou, L., & Zhao, Y. (2015) · Future Oncology · doi:10.2217/fon.15.176 · Cited by 51
Inflammatory fibroblasts in cancer
Lim, H., & Moon, A. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0787-8 · Cited by 48
Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies
Bahrami, A., Khazaei, M., Bagherieh, F., Ghayour‐Mobarhan, M., Maftouh, M., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25798 · Cited by 53
Bouzid, R., Peppelenbosch, M. P., & Buschow, S. I. (2020) · Cancers · doi:10.3390/cancers12051121 · Cited by 52
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00455 · Cited by 47
More than a scaffold: Stromal modulation of tumor immunity
Johansson, A., Hamzah, J., & Ganß, R. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.001 · Cited by 49
A Quick Guide to CAF Subtypes in Pancreatic Cancer
Brichkina, A. I., Polo, P., Sharma, S. D., Visestamkul, N., & Lauth, M. (2023) · Cancers · doi:10.3390/cancers15092614 · Cited by 48
Xu, A. M., Haro, M., Walts, A. E., Hu, Y., John, J., Karlan, B. Y., Merchant, A. A., & Oršulić, S. (2024) · Science Advances · doi:10.1126/sciadv.adk8805 · Cited by 51
Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Yamazaki, M., & Ishimoto, T. (2025) · Cancer Science · doi:10.1111/cas.16443 · Cited by 46
Jiang, G., Xie, W., Wang, H., Du, J., Bai-ping, W., Xu, W., Liu, H., Xiao, P., Liu, Z.-G., Li, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4577 · Cited by 49
“Removing FAPα+ fibroblasts does not alter the number or subtypes of tumor infiltrating T cells, but does result in their activation and secretion of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), two antitumor cytokines secreted by activated Th1 and NK cells [13].”
BackgroundOvercoming immunosuppression in bone metastases
Reinstein, Z. Z., Pamarthy, S., Sagar, V., da Costa, R. B., Abdulkadir, S. A., Giles, F. J., & Carneiro, B. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.004 · Cited by 48
Targeting the Microenvironment in High Grade Serous Ovarian Cancer
Nwani, N. G., Sima, L. E., Nieves‐Neira, W., & Matei, D. E. (2018) · Cancers · doi:10.3390/cancers10080266 · Cited by 49
Tan, H., Xiao, Z., Huang, T., Fang, Z., Liu, Y., & Huang, Z. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685156 · Cited by 47
Emami, L., Faghih, Z. S., Sakhteman, A., Rezaei, Z., Faghih, Z., Salehi, F., & Khabnadideh, S. (2020) · New Journal of Chemistry · doi:10.1039/d0nj03774e · Cited by 46
Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer
Ruscetti, M., Morris, J. P., Mezzadra, R., Russell, J., Leibold, J., Romesser, P. B., Simon, J., Kulick, A., Ho, Y.-J., Fennell, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.028 · Cited by 46
Smart and bioinspired systems for overcoming biological barriers and enhancing disease theranostics
Li, X., Gao, Y., Li, H., Majoral, J., Shi, X., & Pich, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101170 · Cited by 48
Diwanji, R., O’Brien, N. A., Choi, J. E., Nguyen, B., Laszewski, T., Grauel, A. L., Yan, Z., Xu, X., Wu, J., Ruddy, D. A., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0290 · Cited by 47
Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
Huang, Y., Fan, H., & Ti, H. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100902 · Cited by 54
“Finally, CAFs can also contribute to the generation of an immunosuppressant environment by generating cytokines like IL6, growth factors like VEGF [ 118 ,119 ] and platelet-derived growth factors (PDGF), chemokines like CXCL12, and matrix metalloproteinases, TGF-β , and PGE2.”
BackgroundEs, H. A., Zhand, S., Thiery, J. P., & Warkiani, M. E. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa014 · Cited by 46
CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target
Malik, S., Westcott, J. M., Brekken, R. A., & Burrows, F. J. (2021) · Cancers · doi:10.3390/cancers14010086 · Cited by 44
Medical Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Morgan, A. G., Griffin, M., Kameni, L. E., Wan, D. C., Longaker, M. T., & Norton, J. A. (2023) · Biology · doi:10.3390/biology12081044 · Cited by 44
Stroma: Fertile soil for inflammation
Patel, R., Filer, A. D., Barone, F., & Buckley, C. D. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.10.022 · Cited by 50
Cancer Immunotherapy: Whence and Whither
Stambrook, P. J., Maher, J. F., & Farzaneh, F. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0427 · Cited by 46
Dharani, S., Cho, H., Postigo, J., Juillerat, A., Valton, J., Duchateau, P. N., Poirot, L., & Das, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.018 · Cited by 43
Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
Tan, K. W., Evrard, M., Tham, M., Hong, M. L. W., Huang, C. W., Kato, M., Prévost‐Blondel, A., Donnadieu, E., Ng, L. G., & Abastado, J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.978709 · Cited by 45
Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC
Strell, C., Norberg, K. J., Mezheyeuski, A., Schnittert, J., Kuninty, P. R., Moro, C. F., Paulsson, J., Schultz, N. A., Calatayud, D., Löhr, M. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.140 · Cited by 45
“Furthermore, fibroblast activation protein-positive CAFs have been linked to tumour immune evasion (Kraman et al , 2010; Feig et al , 2013) and were found to be associated with a bad prognosis in PDAC (Kawase et al , 2015).”
BackgroundMundry, C. S., Eberle, K. C., Singh, P. K., Hollingsworth, M. A., & Mehla, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188387 · Cited by 44
Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation
Ragunathan, K., Upfold, N. L. E., & Oksenych, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228635 · Cited by 43
“Unlike normal fibroblasts, CAFs suppress the immune response in tumor microenvironment [63].”
BackgroundApplying next-generation sequencing to pancreatic cancer treatment
Mardis, E. R. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.126 · Cited by 45
Shi, Y., Ou, L., Han, S., Li, M., Pena, M. M. O., Pena, E. A., Liu, C., Nagarkatti, M., Fan, D., & Ai, W. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.44 · Cited by 41
Pancreatic cancer: Update on immunotherapies and algenpantucel-L
McCormick, K. A., Coveler, A. L., Rossi, G. R., Vahanian, N. N., Link, C., & Chiorean, E. G. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1093264 · Cited by 44
Fang, J., Hu, B., Li, S., Zhang, C., Liu, Y., & Wang, P. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.7 · Cited by 43
Gui, Y., Aguilar‐Mahecha, A., Krzemien, U., Hosein, A. N., Buchanan, M., Lafleur, J., Pollak, M., Ferrario, C., & Basik, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1268 · Cited by 42
Geng, F., Bao, X., Dong, L., Guo, Q., Guo, J., Xie, Y., Zhou, Y., Yu, B., Wu, H., Wu, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747350 · Cited by 45
Antitumor Effect and Immune Response of Nanosecond Pulsed Electric Fields in Pancreatic Cancer
Zhao, J., Chen, S., Zhu, L., Zhang, L., Liu, J., Xu, D., Tian, G., & Jiang, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621092 · Cited by 48
“HABP1 overexpression is associated with tumor malignancy and patient survival (33).”
BackgroundDual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives
Toledo, B., Picon‐Ruiz, M., Marchal, J. A., & Perán, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415576 · Cited by 42
“Cytotoxic T cell activity was restored, and fast tumour necrosis took place in genetically engineered Lewis lung cancer (LCC) mice when FAPα+ stroma was specifically removed by diphtheria toxin [250].”
BackgroundAli, A., Fuentes, A. C., Skelton, W. P., Wang, Y., McGorray, S. P., Shah, C., Bishnoi, R., Dang, L. H., & Dang, N. H. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1766 · Cited by 41
Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation
Raj, D., Aicher, A., & Heeschen, C. (2015) · Stem Cells · doi:10.1002/stem.2114 · Cited by 44
Cholok, D. J., Lee, E., Lisiecki, J. L., Agarwal, S., Loder, S. J., Ranganathan, K., Qureshi, A. T., Davis, T. A., & Lévi, B. (2016) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001290 · Cited by 44
Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins
Triaca, V., Carito, V., Fico, E., Rosso, P., Fiore, M., Ralli, M., Lambìase, A., Greco, A., & Tirassa, P. (2019) · Aging · doi:10.18632/aging.102499 · Cited by 43
“Maintenance of undifferentiated and self-renewing CSCs relies on the “stem cell niche”, a microenvironment mainly represented by dendritic cells (DCs), tumor associated macrophages (TAMs), fibroblasts, tumor-specific T cells, and neutrophils [11, 12].”
BackgroundTuran, T., Kongpachith, S., Halliwill, K. D., Roelands, J. P., Hendrickx, W., Marincola, F. M., Hudson, T. J., Jacob, H. J., Bedognetti, D., Samayoa, J. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01145-4 · Cited by 43
Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer
Sherman, M. H., & di Magliano, M. P. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-035400 · Cited by 42
Unsworth, A., Anderson, R. L., & Britt, K. L. (2014) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-014-9326-8 · Cited by 41
“In several preclinical studies, targeting FAP genetically or with vaccines or pharmacological agents, resulted in impaired tumor progression inmice [143–145,107,146–148].”
BackgroundWitek, M. A., Aufforth, R., Wang, H., Kamande, J. W., Jackson, J. M., Pullagurla, S. R., Hupert, M. L., Usary, J., Wysham, W. Z., Hilliard, D., et al. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0028-8 · Cited by 40
Verena, A., Zhang, Z., Kuo, H., Merkens, H., Zeisler, J., Wilson, R., Bendre, S., Wong, A. A. W. L., Bénard, F., & Lin, K. (2023) · Molecules · doi:10.3390/molecules28031088 · Cited by 40
“FAP expression is associated with worse prognosis as FAP supports tumor migration [21], angiogenesis [22], metastasis via matrix remodeling in TME [23], and immunomodulatory function [24].”
BackgroundWong, P. F., Gall, M. G., Bachovchin, W. W., McCaughan, G. W., Keane, F. M., & Gorrell, M. D. (2015) · Peptides · doi:10.1016/j.peptides.2015.11.004 · Cited by 42
Meng, Q., Luo, X., Chen, J., Wang, D., Chen, E., Zhang, W., Zhang, G., Zhou, W., Xu, J., & Song, Z. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188443 · Cited by 39
Shin, H., Kim, Y., & Jon, S. (2023) · ACS Nano · doi:10.1021/acsnano.3c00764 · Cited by 41
Tillmanns, J., Widera, C., Habbaba, Y., Galuppo, P., Kempf, T., Wollert, K. C., & Bauersachs, J. K. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.061 · Cited by 39
Du, S., & Barcellos‐Hoff, M. H. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.001 · Cited by 41
Ma, W., Li, N., Zhao, W., Ren, J., Wei, M., Yang, Y., Wang, Y., Fu, X., Zhang, Z., Larson, A. C., et al. (2016) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000434 · Cited by 39
“Apparent diffusion coefficient value may be an ideal method to monitor novel therapy strategies where inhibition of FAP expression and its proteolytic activity can prevent and treat PC.(28,30) There are several limitations in our study.”
MethodAntigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials
Arabi, F., Torabi‐Rahvar, M., Shariati, A., Ahmadbeigi, N., & Naderi, M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.05.009 · Cited by 42
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma
Quatannens, D., Verhoeven, Y., van Dam, P. A., Lardon, F., Prenen, H., Roeyen, G., Peeters, M., Smits, E., & Audenaerde, J. R. M. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108107 · Cited by 40
Clinical cancer research: the past, present and the future
DeVita, V. T., Eggermont, A. M. M., Hellmän, S., & Kerr, D. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.153 · Cited by 40
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 40
“In two mouse models of cancer, a transplanted Lewis lung carcinoma (Kraman et al. 2010) and an autochthonous pancreatic ductal adenocarcinoma (PDA) (Feig et al.”
BackgroundSelf-citationTailoring Natural Killer cell immunotherapy to the tumour microenvironment
Barrow, A. D., & Colonna, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.001 · Cited by 38
Maehira, H., Miyake, T., Iida, H., Tokuda, A., Mori, H., Yasukawa, D., Mukaisho, K., Shimizu, T., & Tani, M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07891-x · Cited by 38
Fu, A., Wang, H., Huo, T., Li, X., Fu, W., Huang, R., & Cao, Z. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00413 · Cited by 38
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis
Balážiová, E., Výmola, P., Hrabal, P., Mateu, R., Zubal, M., Tomáš, R., Netuka, D., Kramář, F., Zemanova, Z., Svobodová, K., et al. (2021) · Cancers · doi:10.3390/cancers13133304 · Cited by 38
Arwert, E. N., Mentink, R. A., Driskell, R. R., Hoste, E., Goldie, S. J., Quist, S., & Watt, F. M. (2011) · Oncogene · doi:10.1038/onc.2011.298 · Cited by 40
Kim, E. J.-H., & Simeone, D. M. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328349e31f · Cited by 37
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Batra, H. V., Mouabbi, J. A., Ding, Q., Şahin, A. A., & Raso, M. G. (2023) · Cancers · doi:10.3390/cancers15225491 · Cited by 43
Maternal Priming of Offspring Immune System inDrosophila
Bozler, J., Kacsoh, B. Z., & Bosco, G. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400852 · Cited by 38
“Though these studies are within an individual and not demonstrated to be passed on to the next generation, the observation raises the possibility that intergenerational downregulation may also occur (Coussens et al. 2013; Kraman et al. 2010; Wetzig et al. 1982).”
BackgroundAdvances in research on the interaction between inflammation and cancer
Song, X., Wang, Y., Zhang, A., & Liu, B. (2019) · Journal of International Medical Research · doi:10.1177/0300060519895347 · Cited by 43
Stouten, I., van Montfoort, N., & Hawinkels, L. J. A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108707 · Cited by 38
“Moreover, in vivo depletion of fibroblast activation protein (FAP)+ stromal cells, a marker abundantly expressed by CAFs, resulted in the inhibition of tumour growth [27].”
BackgroundHolmberg, C., Quante, M., Steele, I. A., Kumar, J. D., Balabanova, S., Duval, C., Czepán, M., Rakonczay, Z., Tiszlavicz, L., Németh, I. B., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs180 · Cited by 41
Hu, M., Qian, C., Hu, Z., Fei, B., & Zhou, H. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0159 · Cited by 40
“Overexpression of FAP-a has been implicated in several human malignancies, including breast cancer, ovarian cancer, pancreatic adenocarcinoma, colon cancer, lung cancer, melanoma, and lymphoma (Henry et al., 2007; Kraman et al., 2010; Lee et al., 2005; Lv et al., 2016).”
Brentnall, T. A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.21453 · Cited by 39
The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts
Huang, Q., Ge, Y., He, Y. T., Wu, J., Tong, Y., Shang, H., Liu, X., Ba, X., Xia, D., Peng, E., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s447350 · Cited by 37
Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells
Saijo, A., Goto, H., Nakano, M., Mitsuhashi, A., Aono, Y., Hanibuchi, M., Ogawa, H., Uehara, H., Kondo, K., & Nishioka, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.016 · Cited by 37
The actin modulator hMENA regulates GAS6‐AXL axis and pro‐tumor cancer/stromal cell cooperation
Melchionna, R., Spada, S., Modugno, F. D., D’Andrea, D., Carlo, A. D., Panetta, M., Mileo, A. M., Sperduti, I., Antoniani, B., Gallo, E., et al. (2020) · EMBO Reports · doi:10.15252/embr.202050078 · Cited by 37
“This scenario is even more detrimental in pancreatic ductal adenocarcinoma (PDAC; Kraman et al , 2010; Provenzano et al , 2012; Shi et al , 2019), a tumor which still lacks effective therapeutic options although estimated to become the second leading cause of cancer-related deaths by 2030 (Hoos et…”
Lin, J., Chuang, C.-P., Lin, J., Huang, F., & Huang, C. (2021) · ACS Sensors · doi:10.1021/acssensors.1c01316 · Cited by 36
Drake, C. G. (2014) · PubMed · Cited by 36
XU, G., GUO, Y., SENG, Z., CUI, G., & QU, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4174 · Cited by 35
Zhao, Y., Liu, Y., Jia, Y., Wang, X., He, J., Zhen, S., Wang, J., & Liu, L. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04250-4 · Cited by 36
Garetto, S., Sardi, C., Martini, E., Roselli, G., Morone, D., Angioni, R., Cianciotti, B. C., Trovato, A. E., Franchina, D. G., Castino, G. F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9280 · Cited by 35
“In the context of tumors, where fibroblasts may be tumor-promoting FAP+ Cancer-Associated Fibroblasts [42], Th2 cells contribute to pro-tumoral inflammation in pancreatic [35] and breast cancers [43].”
BackgroundHaro, M., & Oršulić, S. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00098 · Cited by 42
Brennen, W. N., Thorek, D. L. J., Jiang, W., Krueger, T. E. G., Antony, L., Denmeade, S. R., & Isaacs, J. T. (2020) · Immunotherapy · doi:10.2217/imt-2020-0066 · Cited by 35
A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)
Kelly, J. M., Jeitner, T. M., Ponnala, S., Williams, C. M., Nikolopoulou, A., DiMagno, S. G., & Babich, J. W. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01593-1 · Cited by 35
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.